Glial-restricted progenitor cell (GRP)

Glial-restricted progenitor cells (GRPs) are lineage-restricted precursor cells found in the central nervous system with the capacity to differentiate into astrocytes and oligodendrocytes but not neurons. They are considered early-stage glial precursors derived from embryonic tissue or stem cells. GRPs have been investigated as candidates for transplantation therapies aimed at repairing or regenerating damaged neural tissue in neurodegenerative diseases and traumatic injuries such as spinal cord injury. These cells can be purified using markers like A2B5 and expanded ex vivo due to their self-renewal capability. Transplantation studies show that GRPs survive well after grafting, migrate within host tissue, differentiate appropriately into glia, improve lesion environments without increasing pain sensitivity, but often do not result in significant functional recovery unless combined with other interventions. While promising as a regenerative medicine tool, they are not molecular therapeutic targets like receptors or enzymes but rather represent a cellular therapy approach.[1][2][3][4]

Other names

glial-restricted precursor cellglial progenitor cellhGRP (for human-derived)allogeneic glial progenitor cell